文献速递临床试验与 GCP基础与转化研究

诱导多能干细胞来源的角膜上皮用于移植手术:日本单臂、开放标签、首次人体干预研究

Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
PubMed 文献 · Lancet · 2024-11-07

该研究在4例角膜缘干细胞缺乏症(LSCD)患者4只眼上移植同种异体人iPSC来源的角膜上皮细胞片(iCEPSs),52周随访及额外1年安全性监测期间未发生肿瘤发生或临床排斥等严重不良事件,所有治疗眼疾病分期、矫正远视力及角膜混浊均改善,患者1和2的疗效优于患者3和4。

要点

  • iCEPS移植在2年观察期内未出现肿瘤发生或临床排斥等严重不良事件。
  • 52周时所有治疗眼疾病分期改善、矫正远视力提高、角膜混浊减轻。
  • 患者1和2获得的总体有益疗效优于患者3和4。

核心结论

  • iCEPS移植治疗LSCD在研究期间被认为是安全的,计划开展更大规模临床试验进一步研究该操作的疗效。

研究设计与样本

  • 非随机、单臂临床研究,纳入大阪大学医院眼科的4例LSCD患者共4只眼。
  • 患者包括44岁女性特发性LSCD(患者1)、66岁男性眼黏膜类天疱疮(患者2)、72岁男性特发性LSCD(患者3)和39岁女性中毒性表皮坏死松解症(患者4)。
  • 将同种异体人iPSC来源的角膜上皮细胞片(iCEPSs)移植到患眼,分两组序贯进行HLA不匹配手术,患者1和2接受低剂量环孢素,患者3和4未接受。
  • 主要结局为安全性(不良事件),在52周随访期及额外1年安全性监测期内持续监测;次要结局反映疗效。
  • 研究注册号UMIN000036539,已完成;患者入组时间为2019年6月17日至2020年11月16日。

主要发现

  • 52周随访期内共发生26例不良事件(治疗眼18例轻度、1例中度,7例轻度非眼部事件),额外1年安全性监测期内记录9例。
  • 整个2年观察期内未发生肿瘤发生或临床排斥等严重不良事件。
  • 52周时次要疗效指标显示所有治疗眼疾病分期改善、矫正远视力提高、角膜混浊减轻。
  • 角膜上皮缺损、主观症状、生活质量问卷评分和角膜新生血管大多改善或不变。
  • 患者1和2获得的总体有益疗效优于患者3和4。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The loss of corneal epithelial stem cells from the limbus at the edge of the cornea has severe consequences for vision, with the pathological manifestations of a limbal stem-cell deficiency (LSCD) difficult to treat. Here, to the best of our knowledge, we report the world's first use of corneal epithelial cell sheets derived from human induced pluripotent stem cells (iPSCs) to treat LSCD. METHODS: This non-randomised, single-arm, clinical study involved four eyes of four patients with LSCD at the Department of Ophthalmology, Osaka University Hospital. They comprised a woman aged 44 years with idiopathic LSCD (patient 1), a man aged 66 years with ocular mucous membrane pemphigoid (patient 2), a man aged 72 years with idiopathic LSCD (patient 3), and a woman aged 39 years with toxic epidermal necrosis (patient 4). Allogeneic human iPSC-derived corneal epithelial cell sheets (iCEPSs) were transplanted onto affected eyes. This was done sequentially in two sets of HLA-mismatched surgeries, with patients 1 and 2 receiving low-dose cyclosporin and patients 3 and 4 not. The primary outcome measure was safety, ascertained by adverse events. These were monitored continuously throughout the 52-week follow-up period, and during an additional 1-year safety monitoring period. Secondary outcomes, reflective of efficacy, were also recorded. This study is registered with UMIN, UMIN000036539 and is complete. FINDINGS: Patients were enrolled between June 17, 2019 and Nov 16, 2020. We had 26 adverse events during the 52-week follow-up period (consisting of 18 mild and one moderate event in treated eyes, and seven mild non-ocular events), with nine recorded in the additional 1-year safety monitoring period. No serious adverse events, such as tumourigenesis or clinical rejection, occurred during the whole 2-year observational period. At 52 weeks, secondary measures of efficacy showed that the disease stage had improved, corrected distance visual acuity was enhanced, and corneal opacification had diminished in all treated eyes. Corneal epithelial defects, subjective symptoms, quality-of-life questionnaire scores and corneal neovascularisation mostly improved or were unchanged. Overall, the beneficial efficacy outcomes achieved for patients 1 and 2 were better than those achieved for patients 3 and 4. INTERPRETATION: iCEPS transplantation for LSCD was found to be safe throughout the study period. A larger clinical trial is planned to further investigate the efficacy of the procedure. FUNDING: The Japan Agency for Medical Research and Development, the Ministry of Education, Culture, Sports, Science, and Technology-Japan, and the UK Biotechnology and Biological Sciences Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Soma T, Oie Y, Takayanagi H, et al. Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan. Lancet. 2024. PMID: 39522528. doi:10.1016/S0140-6736(24)01764-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。